Aegerion Pharma (AEGR) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Cowen Cuts Price Target on Aegerion Pharma (AEGR) Following 3Q Results
November 10, 2015 8:35 AM ESTCowen maintained a Market Perform rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and cut the price target to $15.00 (from $25.00), following the company's 3Q earnings report. Juxtapid sales were $58.8MM, ahead of consensus of $54MM. Myalept revenue of $8.5MM was ahead of consensus of... More
